Skip to Main Content
Contribute Try STAT+ Today

On the heels of Teladoc’s landscape-shifting deal to buy Livongo, telemedicine rival MDLive is setting its sights on a public offering early next year, the company’s chief executive officer told STAT.

The offering, which is still in the early stages, would take place some time in January or February of next year, according to CEO Charles Jones. Jones added that Teladoc’s $18.5 billion planned acquisition of Livongo, announced earlier this month, bolstered his decision to push the company toward a market debut. Teladoc became the first telemedicine company to IPO in 2015, and remains the only major telehealth provider that is publicly traded.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.